MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Ocular Therapeutix escapes SEC probe

Ocular Therapeutix escapes SEC probe

By

Ocular Therapeutix logoThe SEC recently closed its probe into Ocular Therapeutix (NSDQ:OCUL) and found no wrongdoing in the investigation.

Ocular Therapeutix received a subpoena from the SEC on Dec. 15, 2017, for documents and information pertaining to its Dextenza 0.4mg and related communication with the FDA, investors and other parties. The company received a second subpoena on Aug. 21, 2018, for documents and information about its participation in two investor conferences in June 2017.

Get the full story on our sister site, Drug Delivery Business.

More recent news

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].